Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

A Study to Evaluate CG-105-12 in Patients With Relapsed/Refractory Multiple Myeloma — Stella

Home/Relapsed/Refractory/A Study to Evaluate CG-105-12 in Patients With Relapsed/Refractory Multiple Myeloma

View on ClinicalTrials.gov

Recruiting

Back to Relapsed/Refractory trials

A Study to Evaluate CG-105-12 in Patients With Relapsed/Refractory Multiple Myeloma

Early Phase 1 — Very small initial tests in humans, typically just a few people, to make sure the treatment is safe enough to study further.

Trial locations(1 site)

China

The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi

Key details

Phase

Very early testing

Sponsor

The First Affiliated Hospital of Nanchang University

Collaborators

Cells & Genes Biotech (Shanghai) Co.,Ltd

Enrollment target

~12 participants

Started

September 2024

Primary completion

April 2026

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

18 Years – 75 Years

Last updated May 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.